References
- Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the department of Veterans Affairs (VA) health care system: historical perspective, lessons learned and next steps. Sub Abuse 2018; epub ahead of print.
- Bohnert AS, Ilgen MA, Galea S, et al. Accidental poisoning mortality among patients in the Department of Veterans Affairs Health System. Medical Care. 2011;49(4):393–396.
- The Management of Substance Use Disorders Work Group. Department of Veterans Affairs and Department of Defense Clinical Practice Guideline for the Management of Substance Use Disorders. 2015. Retrieved from: https://www.healthquality.va.gov/guidelines/MH/sud/VADODSUDCPGRevised22216.pdf
- Oliva E, Trafton J, Harris AHS, et al. Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse. 2013;39(2):103–107.
- Stein BD, Sorbero M, Dick AW, et al. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–1212.
- Thomas CP, Doyle E, Kreiner PW, et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend. 2017;181:213–218.
- Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychology of Addictive Behaviors. 2011;25(2):215–224.
- Wakeman SE, Barnett ML. Primary Care and the opioid-overdose crisis—buprenorphine myths and realities. New Eng J Med. 2018;379(1):1–4.